Coverage
-
August 26, 2016
Aveo Pharmaceuticals Inc.'s board has agreed to reform itself and the company's internal policies following an investor's derivative suit claiming it lied about the success of a clinical trial for a kidney cancer medication, according to a preliminary settlement submitted Thursday to a Massachusetts federal court.
1 other articles on this case.
View all »